CFDE Data Portal | Search MAD2L1BP

	Label	Description
	MAD2L1BP associations Collection (Entity type)	Associations for MAD2L1BP_associations
	MAD2L1BP Up Gene Set (Entity type)	A Gene Set from LINCS
	MAD2L1BP Down Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	MAD2L1BP associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE148200 0 V 2 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	MAD2L1BP Gene (Entity type)	ENSG00000124688 - MAD2L1 binding protein
	GSE111247 temozolomide LN-308 2 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 elesclomol SU-DHL-4 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

MAD2L1BP associations

Associations for MAD2L1BP_associations

MAD2L1BP Up

A Gene Set from LINCS

MAD2L1BP Down

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

A Gene Set from LINCS

MAD2L1BP associations.tsv

A file from IDG as part of the Harmonizome project

GSE148200 0 V 2 GEMCITABINE HUMAN UP

A Gene Set from LINCS

MAD2L1BP

ENSG00000124688 - MAD2L1 binding protein

GSE111247 temozolomide LN-308 2 v 13 human up

A Gene Set from LINCS

GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn

A Gene Set from LINCS

GSE228263 elesclomol SU-DHL-4 0 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.